Αρχική World News Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or... World News Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma Από Ogkologos - 20 Ιανουαρίου, 2025 1003 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR How we can reduce cancer risk in inflammatory bowel disease patients... 23 Αυγούστου, 2022 When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer... 17 Δεκεμβρίου, 2021 FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy 5 Σεπτεμβρίου, 2024 Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors 27 Μαρτίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Brothers Break Down After Seeing Their Parents For First Time In... Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis “World’s Tiniest Baby” Has Been Released From The Hospital Keeping progress in oncology on the agenda: ESMO honours recipients of...